Login
$WVE
$3.21 +$0.03 (0.94%) Close

Insider Transactions

What Wave Life Sciences, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.

Insider trades

3 months 12 months
Open-market buys 0 6
Sells 4 47
Total trades 13 94

Shares traded

3 months 12 months
Acquired 92,600 92,600
Disposed 23,996 23,996
Net activity +68,604 +68,604

Common stock only — 81 reported trades in the last 12 months are in a security these totals do not cover.

See the story behind these numbers

View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.

Open-market buyer Disclosed 10b5-1 Heavy discretionary Sign up free

All transactions

Insider Relation Date Transaction Shares Price Value Shares held
Takanashi Ken Director Oct 05 Grant / award · A +10,700 — — 30,779
Tan Aik Na Director Oct 05 Grant / award · A +10,700 — — 35,668
Wagner Heidi L Director Oct 05 Grant / award · A +10,700 — — 55,630
Ra Capital MANAGEMENT, L.p. Director Oct 05 Grant / award · A +10,700 — — 39,515
Henry Christian O Director Oct 05 Grant / award · A +10,700 — — 23,400
Corrigan Mark Director Oct 05 Grant / award · A +10,700 — — 39,515
Rawcliffe Adrian Director Oct 05 Grant / award · A +10,700 — — 10,700
Verdine Gregory L. Director Oct 05 Grant / award · A +10,700 — — 200,917
Rawcliffe Adrian Director Aug 12 Disclosed 10b5-1 sale · S −12,700 $5.29 −$67.2K 0
Wagner Heidi L Director Aug 11 Disclosed 10b5-1 sale · S −7,000 $6.01 −$42.1K 44,930
Wagner Heidi L Director Aug 11 Exercise / conversion · M +7,000 $5.97 +$41.8K 51,930
Tan Aik Na Director Aug 11 Open-market sale · S −432 $6.01 −$2.6K 24,968
Takanashi Ken Director Aug 11 Sale for tax withholding · S −3,864 $6.01 −$23.2K 20,079
Ra Capital MANAGEMENT, L.p. Director Mar 30 Open-market buy · P +971,091 $6.50 +$6.31M 26,975,505
Ra Capital MANAGEMENT, L.p. Director Mar 27 Open-market buy · P +2,495,623 $6.43 +$16M 26,004,414
Ra Capital MANAGEMENT, L.p. Director Mar 26 Open-market buy · P +351,224 $6.38 +$2.24M 23,508,791
Ra Capital MANAGEMENT, L.p. Director Mar 26 Open-market buy · P +4,954,558 $6.06 +$30M 23,157,567
Takanashi Ken Director Mar 23 Derivative Conversion · C +3,901,348 — — 9,606,408
Francis Chris See Remarks Feb 26 Disclosed 10b5-1 sale · S −15,294 $15.00 −$229K 61,867
Francis Chris See Remarks Feb 26 Exercise / conversion · M +15,294 $4.75 +$72.6K 77,161

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support